Literature DB >> 8559480

High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients.

H A Austin1, D T Boumpas, E M Vaughan, J E Balow.   

Abstract

BACKGROUND: The pleomorphic nature of lupus nephritis has confounded efforts to refine estimates of prognosis. Consideration of interactions among prognostic factors may help to identify high-risk patients.
METHODS: By univariate and multivariate survival analysis, race and attributes of severe active lupus nephritis were evaluated as potentially important prognostic factors in 166 patients upon entry into prospective therapeutic trials of lupus kidney disease.
RESULTS: Black patients were significantly more likely than others to develop renal insufficiency. Cellular crescents emerged as the most predictive active pathological feature and interstitial fibrosis was the strongest chronic histological prognostic factor. Combinations of these morphological attributes identified particularly high-risk individuals. Patients with 50% or more cellular crescents and those with less extensive cellular crescents plus moderate to severe interstitial fibrosis were at markedly increased risk for doubling serum creatinine compared to those who lacked these histologic features (P < 0.0001). Azotaemia, anaemia, hypocomplementaemia, hypertension, tubular atrophy and glomerular sclerosis were also associated with an increased probability of renal function deterioration. Serum creatinine, haematocrit, race, and kidney pathology data emerged as independent predictors of renal insufficiency. Black patients in this study were more likely than the others to have high-risk histological features, including extensive cellular crescents (> or = 50%) and moderate to severe interstitial fibrosis, prior to randomization.
CONCLUSIONS: Combinations of high-risk demographic, clinical and histological attributes identify patients at increased risk for progressive renal function deterioration. Several factors, including the severity of kidney biopsy findings, probably contribute to the poor prognosis of Black patients in this study population.

Entities:  

Mesh:

Year:  1995        PMID: 8559480

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  49 in total

1.  Urinary vascular cell adhesion molecule, but not neutrophil gelatinase-associated lipocalin, is associated with lupus nephritis.

Authors:  Adnan N Kiani; Tianfu Wu; Hong Fang; Xin J Zhou; Chul W Ahn; Laurence S Magder; Chandra Mohan; Michelle Petri
Journal:  J Rheumatol       Date:  2012-04-15       Impact factor: 4.666

Review 2.  Role of TWEAK in lupus nephritis: a bench-to-bedside review.

Authors:  Jennifer S Michaelson; Nicolas Wisniacki; Linda C Burkly; Chaim Putterman
Journal:  J Autoimmun       Date:  2012-06-22       Impact factor: 7.094

3.  Defining the role of mycophenolate mofetil in the treatment of proliferative lupus nephritis.

Authors:  Oliver Lenz; Alessia Fornoni; Gabriel Contreras
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  The Revisited Classification of GN in SLE at 10 Years: Time to Re-Evaluate Histopathologic Lesions.

Authors:  Suzanne Wilhelmus; Charles E Alpers; H Terence Cook; Franco Ferrario; Agnes B Fogo; Mark Haas; Kensuke Joh; Laure-Hélène Noël; Surya V Seshan; Jan A Bruijn; Ingeborg M Bajema
Journal:  J Am Soc Nephrol       Date:  2015-07-07       Impact factor: 10.121

5.  Histopathological indicators of disease outcome in class IV lupus nephritis: a revisit of various indices.

Authors:  Manish Rathi; Krishan Lal Gupta; Kusum Joshi; Pramod K Gupta; Aman Sharma; Harbir Singh Kohli; Vivekanand Jha; Vinay Sakhuja
Journal:  Rheumatol Int       Date:  2015-03-11       Impact factor: 2.631

6.  Serum osteoprotegrin (OPG) in subclinical atherosclerosis in systemic lupus erythematosus.

Authors:  A N Kiani; P Aukrust; T Ueland; I Hollan; E Barr; L S Magder; M Petri
Journal:  Lupus       Date:  2016-12-06       Impact factor: 2.911

7.  Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy.

Authors:  Howard A Austin; Gabor G Illei; Michelle J Braun; James E Balow
Journal:  J Am Soc Nephrol       Date:  2009-03-18       Impact factor: 10.121

8.  Retrospective analysis of the renal outcome of pediatric lupus nephritis.

Authors:  Li-Chieh Wang; Yao-Hsu Yang; Meng-Yao Lu; Bor-Luen Chiang
Journal:  Clin Rheumatol       Date:  2004-06-02       Impact factor: 2.980

9.  Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study.

Authors:  David Isenberg; Gerald B Appel; Gabriel Contreras; Mary A Dooley; Ellen M Ginzler; David Jayne; Jorge Sánchez-Guerrero; David Wofsy; Xueqing Yu; Neil Solomons
Journal:  Rheumatology (Oxford)       Date:  2009-11-20       Impact factor: 7.580

Review 10.  Usefulness of ISN/RPS classification of lupus nephritis.

Authors:  Ken-Ei Sada; Hirofumi Makino
Journal:  J Korean Med Sci       Date:  2009-01-28       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.